Oligonucleotide Therapeutics

Oligonucleotide Therapeutics

Global Oligonucleotide Therapeutics Market to Reach US$4.9 Billion by 2030

The global market for Oligonucleotide Therapeutics estimated at US$2.8 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2023-2030. Antisense / RNAI Oligonucleotides Technology, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Other Technologies segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$762.6 Million While China is Forecast to Grow at 7.9% CAGR

The Oligonucleotide Therapeutics market in the U.S. is estimated at US$762.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$744.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Global Oligonucleotide Therapeutics Market – Key Trends & Drivers Summarized

What Are Oligonucleotide Therapeutics and Why Are They a Game Changer?

Oligonucleotide therapeutics are a rapidly emerging class of drugs that use synthetic oligonucleotides (short strands of DNA or RNA) to modulate gene expression or protein function within cells. These therapies are designed to silence, repair, or alter the expression of specific genes, making them highly targeted compared to traditional small-molecule drugs. Oligonucleotide therapeutics include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, which are being used to treat a range of diseases, including genetic disorders, cancers, and cardiovascular conditions. Their ability to address diseases at the molecular level represents a significant advancement in precision medicine, offering new hope for previously untreatable conditions. As research into genetic and rare diseases progresses, oligonucleotide therapeutics are becoming a vital component of the pharmaceutical landscape, driving significant interest from both the scientific community and pharmaceutical companies.

How Are Technological Innovations Pushing the Boundaries of Oligonucleotide Therapeutics?

Technological advancements in oligonucleotide chemistry, delivery systems, and manufacturing processes are playing a pivotal role in the success of oligonucleotide therapeutics. Early limitations, such as instability in the bloodstream and difficulties in targeting specific tissues, have been addressed through modifications like phosphorothioate backbones and lipid nanoparticle delivery systems, which enhance the stability and bioavailability of oligonucleotides. Furthermore, innovations in RNA interference (RNAi) and gene editing technologies, such as CRISPR, have significantly expanded the scope of oligonucleotide-based therapies. Advances in artificial intelligence (AI) and computational biology are also aiding in the design of more effective and precise oligonucleotides, reducing off-target effects and improving therapeutic efficacy. Additionally, the development of high-throughput synthesis technologies allows for the rapid production of large libraries of oligonucleotides, accelerating drug discovery and development processes. These technological breakthroughs are helping to overcome the traditional challenges associated with oligonucleotide therapeutics, making them increasingly viable for mainstream clinical use.

What Diseases Are Oligonucleotide Therapeutics Targeting and Why Is Demand Growing?

The expanding therapeutic potential of oligonucleotides has positioned them as a key solution for addressing a wide range of genetic and rare diseases. One of the primary areas of focus is rare genetic disorders, where oligonucleotide therapeutics can target the root cause of the disease by silencing or modifying defective genes. Approved treatments like Spinraza (for spinal muscular atrophy) and Tegsedi (for hereditary transthyretin-mediated amyloidosis) have set the stage for further exploration into neuromuscular diseases, oncology, and metabolic conditions. In oncology, oligonucleotide therapeutics are being explored for their ability to inhibit oncogenes or enhance the expression of tumor suppressor genes, creating novel avenues for cancer treatment. Additionally, they are showing promise in cardiovascular diseases, ocular disorders, and viral infections. The personalized nature of these therapies is driving demand, as they offer tailored treatment options based on the genetic makeup of individual patients, a trend that aligns with the broader move toward precision medicine.

What Are the Key Drivers Fueling Growth in the Oligonucleotide Therapeutics Market?

The growth in the oligonucleotide therapeutics market is driven by several factors, primarily the increasing number of approved therapies and their expanding therapeutic applications. Advances in RNA-targeting technologies, such as RNA interference and antisense oligonucleotides, have opened new doors for treating diseases with high unmet medical needs. The growing focus on precision medicine and the development of treatments for rare genetic disorders are also significant growth drivers, as these therapies offer targeted, personalized solutions that conventional treatments cannot provide. Additionally, ongoing research into cancer, cardiovascular diseases, and other chronic conditions is pushing the demand for oligonucleotide-based therapies. Technological advancements in delivery methods, such as lipid nanoparticles and exon-skipping technologies, are further improving the effectiveness and safety profiles of these drugs. Increased investment in biotechnology, along with regulatory support for accelerated drug approvals, is also contributing to the market’s expansion. As pharmaceutical companies continue to invest in oligonucleotide research and development, the market is expected to see robust growth in the coming years.

Select Competitors (Total 44 Featured) -

• Alnylam Pharmaceuticals, Inc.
• AnaBioTec NV
• Arrowhead Pharmaceuticals, Inc.
• Avidity Biosciences
• Axispharm Laboratories Ltd.
• Axolabs
• Bachem AG
• baseclick GmbH
• Bio Basic Inc.
• Biogen, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.